- Home
- PBT vs ATXS Comparison
PBT vs ATXS Comparison
Compare PBT & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- ATXS
- Stock Information
- Founded
- PBT 1980
- ATXS 2008
- Country
- PBT United States
- ATXS United States
- Employees
- PBT N/A
- ATXS N/A
- Industry
- PBT Oil & Gas Production
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- PBT Energy
- ATXS Health Care
- Exchange
- PBT Nasdaq
- ATXS Nasdaq
- Market Cap
- PBT 475.4M
- ATXS 401.2M
- IPO Year
- PBT N/A
- ATXS 2015
- Fundamental
- Price
- PBT $10.52
- ATXS $3.90
- Analyst Decision
- PBT
- ATXS Strong Buy
- Analyst Count
- PBT 0
- ATXS 6
- Target Price
- PBT N/A
- ATXS $30.00
- AVG Volume (30 Days)
- PBT 81.2K
- ATXS 536.8K
- Earning Date
- PBT 01-01-0001
- ATXS 05-27-2025
- Dividend Yield
- PBT 3.94%
- ATXS N/A
- EPS Growth
- PBT N/A
- ATXS N/A
- EPS
- PBT 0.55
- ATXS N/A
- Revenue
- PBT $27,114,144.00
- ATXS N/A
- Revenue This Year
- PBT N/A
- ATXS N/A
- Revenue Next Year
- PBT N/A
- ATXS N/A
- P/E Ratio
- PBT $18.56
- ATXS N/A
- Revenue Growth
- PBT N/A
- ATXS N/A
- 52 Week Low
- PBT $8.01
- ATXS $3.56
- 52 Week High
- PBT $14.26
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- PBT 62.56
- ATXS 33.88
- Support Level
- PBT $9.73
- ATXS $4.13
- Resistance Level
- PBT $10.20
- ATXS $5.47
- Average True Range (ATR)
- PBT 0.34
- ATXS 0.40
- MACD
- PBT 0.07
- ATXS -0.05
- Stochastic Oscillator
- PBT 97.37
- ATXS 4.85
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.